| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/06/2008 | WO2008025781A1 Bifeprunox doses for treating schizophrenia |
| 03/06/2008 | WO2008025780A1 Titration schedule for bifeprunox for treating schizophrenia and kits for use therein |
| 03/06/2008 | WO2008025777A1 Novel piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 03/06/2008 | WO2008025736A1 Substituted benzimidazolone derivatives, medicaments comprising them and their use |
| 03/06/2008 | WO2008025539A1 Heterocyclic fxr binding compounds |
| 03/06/2008 | WO2008025361A1 3-(1h-indol-3-yl) indan-1-ylamine derivatives for the treatment of depression and anxiety |
| 03/06/2008 | WO2008025148A1 Method of inhibition of respiratory depression using positive allosteric ampa receptor modulators |
| 03/06/2008 | WO2008011177A3 Medicinal delivery system and related methods |
| 03/06/2008 | WO2008006795A3 Indole compounds |
| 03/06/2008 | WO2008005956A3 Pyrrolotriazine kinase inhibitors |
| 03/06/2008 | WO2008004191A3 Process for the preparation of enantiomerically pure salts of n-methyl-3- ( 1-naphthaleneoxy) -3- (2-thienyl) propanamine |
| 03/06/2008 | WO2008003855A3 Use of 2-benzoyl-imidazopyridines in therapeutics |
| 03/06/2008 | WO2008003854A3 Derivatives of 2-benzoyl-imidazopyridines, preparation method thereof and use of same in therapeutics |
| 03/06/2008 | WO2007146225A3 Heterocyclic aspartyl protease inhibitors |
| 03/06/2008 | WO2007131154A3 Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness |
| 03/06/2008 | WO2007125398A3 : sulfonamide compounds as antagonists of the n-type calcium channel |
| 03/06/2008 | WO2007109749A3 Methods for preventing and treating amyloidogenic diseases |
| 03/06/2008 | WO2007106986A8 Dosing regimes for lh or hcg and epo for treatment of neurological disorders |
| 03/06/2008 | WO2007100664A3 Modulators of muscarinic receptors |
| 03/06/2008 | WO2007096193A3 Radiolabelled carbamates |
| 03/06/2008 | WO2007087154A3 Methods for enhancing therapeutic effects of a neurotoxin |
| 03/06/2008 | WO2006096404A8 Treatment of amyotrophic lateral sclerosis with norethindrone and anal0gues |
| 03/06/2008 | US20080058514 ceramide-like inhibitors; novel intermediates formed during the synthesis; Glycosphingolipids |
| 03/06/2008 | US20080058430 Method For Selecting Allosteric Regulators Of Class III G Protein-Coupled Receptors |
| 03/06/2008 | US20080058424 Novel pharmaceutical formulations of modafinil |
| 03/06/2008 | US20080058423 Melanin concentrating hormone antagonists |
| 03/06/2008 | US20080058420 A mixture of excipients not promoting the conversion of gabapentin into the corresponding lactamic impurity; including a sliding agent, e.g., calcium phosphate, a lubricant either hydrogenated castor oil or glyceryl tribehenate, and optionally a diluent saccharide; capsules; storage stability; nontoxic |
| 03/06/2008 | US20080058416 Administering a ketogenic material to produce a ketosis to provide effects of antidepressants, anxiolytic agents, cognition activators, and/or analgesics; preferred materials produce such that the total concentration of acetoacetate and (R)-3-hydroxybutyrate in the blood is raised to 0.1-30 mM. |
| 03/06/2008 | US20080058407 Methods of improving the pharmacokinetics of doxepin |
| 03/06/2008 | US20080058398 1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-(3-{[4-methyl-5-(4-methyl-1,3-oxazol-5-yl)-4H-1,2,4-triazol-3-yl]thio}propyl)-3-azabicyclo[3.1.0]hexane tartrate; antipsychotic agents; nuclear magnetic resonance |
| 03/06/2008 | US20080058396 Administering bryostatins as activators and Protein Kinase C, for stimulation of dendritic spine density |
| 03/06/2008 | US20080058391 Novel compounds |
| 03/06/2008 | US20080058382 Polyamine compounds |
| 03/06/2008 | US20080058380 2-{[2-(3,5-difluorophenyl)acetyl]amino}-N-{5-[2-(isopropoxymethyl)phenyl]-1,3-thiazol-2-yl}propanamide; neuroprotectant; neurodegenerative diseases: Alzheimer's and Parkinson's disease, Down syndrome, amyloid angiopathy and cerebrovascular disorders |
| 03/06/2008 | US20080058376 Useful in treatment of diseases through the inhibition of sodium ion flux through voltage-dependent sodium channels; treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels; neuropathic pain |
| 03/06/2008 | US20080058365 Fused heterocyclic compounds |
| 03/06/2008 | US20080058361 Tetrahydrobenzfluorene derivatives |
| 03/06/2008 | US20080058356 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists |
| 03/06/2008 | US20080058349 Cognitive impairment, Alzheimer's Disease, neurodegeneration and dementia; Beta site APP Cleaving Enzyme (BACE) inhibitors; beta-secretase inhibitors; 3,3-Difluoro-8-(2',6-difluoro-3'-methoxybiphenyl-3-yl)-8-pyridin-4-yl-2,3,4,8-tetrahydroimidazo[1,5-a]pyrimidin-6-amine acetate for example |
| 03/06/2008 | US20080058345 Combination Therapy with Mecamylamine for the Treatment of Mood Disorders |
| 03/06/2008 | US20080058344 Enantiomers of 2'-fluoralkyl-6-nitroquipazine as serotonin transporter positron emission tomography imaging agents and antidepressant therapeutics |
| 03/06/2008 | US20080058343 Heterocyclic substituted piperazine compounds with cxcr3 antagonist activity |
| 03/06/2008 | US20080058339 4-phenyl-3-substituted pyridazine compounds such as tert-Butyl 4-[((6-[4-(methylsulfonyl)phenyl]pyridazin-3-yl)oxy)methyl]-piperidine-1-carboxylate; agonists of the G-protein-coupled receptor GPR119; diabetes and obesity; use with a dipeptidyl peptidase IV (DPP IV) inhibitor |
| 03/06/2008 | US20080058336 Secretase inhibitor |
| 03/06/2008 | US20080058335 Pain, inflammatory or immune disorders, neurological disorders, cancers of the immune system, respiratory disorders, cardiovascular disorders, neuroprotection; e.g. 5-chloro-N-[(2Z)-5-(1-hydroxy-1-methylethyl)-3-[((cis)-3-methoxycyclobutyl)methyl]-4-methyl-1,3-thiazol-2(3H)-ylidene]-2-methoxybenzamide |
| 03/06/2008 | US20080058331 Inhibitors for GlyT-1 |
| 03/06/2008 | US20080058330 Compounds and Combinations Thereof for Inhibiting Beta-Amyloid Production and Methods of Use Thereof |
| 03/06/2008 | US20080058329 Novel indane compounds |
| 03/06/2008 | US20080058328 Substituted 4-phenyltetrahydroisoquinolines, pharmaceuitcal compositions comprising them and therapeutic methods for their use |
| 03/06/2008 | US20080058325 Compounds, methods and pharmaceutical compositions for inhibiting parp |
| 03/06/2008 | US20080058324 Alpha-Keto Carbonyl Calpain Inhibitors |
| 03/06/2008 | US20080058319 Fused ring heterocycles as potassium channel modulators |
| 03/06/2008 | US20080058318 Administering high dosage |
| 03/06/2008 | US20080058313 Tetrahydro-2h-indazole pyrazole cannabinoid modulators |
| 03/06/2008 | US20080058311 Antagonizing N-type calcium channels; use as analgesic, neurodegenerative diseases, brain injury, bronchial asthma, unstable angina and irritable colitis, drug withdrawal symptoms; t-butyl 2-[4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-piperidinyl]-2-oxoethylcarbamate for example |
| 03/06/2008 | US20080058308 2-carbonylamino-4,6-dihydrothieno[2,3-c]furans such as ethyl 2-{[2-fluoro-6-(trifluoromethyl)benzoyl]amino}-4-methyl-4,6-dihydrothieno[2,3-c]furan-3-carboxylate; CB2 receptors ligands for immune and inflammatory conditions; pain; neuroprotectants |
| 03/06/2008 | US20080058307 Novel compounds as cannabinoid receptor ligands |
| 03/06/2008 | US20080058302 Sulfamoyl Benzamides and Methods of Their Use |
| 03/06/2008 | US20080058298 Blocking hedgehog protein transduction signal passageway using alkaloid steroid |
| 03/06/2008 | US20080058284 Pharmaceutical compositions of semicarbazones and/or thiosemicarbazones and/or their derivatives and products of these compositions and their uses as anticonvulsant, anti-nociceptive and anti-inflammatory agents, and in the angiogenic therapy |
| 03/06/2008 | US20080058276 Cis, trans isomerization; serine, threonine profile; therapy, prevention neurodegenerative disorders |
| 03/06/2008 | US20080058273 Brain disorders; antitumor agents |
| 03/06/2008 | US20080058260 Reversible inhibition of pyramidal gap junction activity |
| 03/06/2008 | US20080057515 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 03/06/2008 | US20080057509 Defects in Periaxin Associated with Myelinopathies |
| 03/06/2008 | US20080057120 controlled release tablet of bupropion hydrobromide for reducing the ratio of the maximum/minimum plasma bupropion hydrobromide concentration (Cmax/Cmin) while maintaining bupropion plasma levels within the therapeutic window upon administration to a patient; more stable than buproin hcl |
| 03/06/2008 | US20080057119 low dosage of zolpidem, or zolpidem hemitartrate when formulated for delivery across the oral mucosa, can induce rapid onset of sleep without residual sedative effects upon awakening 2-4 hours late |
| 03/06/2008 | US20080057118 Divalproex pharmaceutical compositions |
| 03/06/2008 | US20080057117 Pharmaceutical composition made up of cannibus extracts |
| 03/06/2008 | US20080057115 2-propyloctanoic acid for treating neurodegenerative diseses contained in a capsule, internally taken safely without feeling acidness, pain, burning sensation in the oral cavity, dissoved quickly in stomach without delay; shell comprises gelatin, sacchride as base and glycerine as plasticizer, a fat |
| 03/06/2008 | US20080057076 Novel fibroblast growth factors |
| 03/06/2008 | US20080057069 Method of increasing trafficking of endothelial progenitor cells to ischemia-damaged tissue |
| 03/06/2008 | US20080057057 Anti-Lipid Rafts Antibodies |
| 03/06/2008 | US20080057055 Human polynucleotide phosphorylase (hPNPaseold-35 or OLD-35); arthritis, atherosclerosis and Alzheimer's disease |
| 03/06/2008 | US20080057028 Vegf-C or Vegf-D Materials and Methods for Stimulation of Neural Stem cells |
| 03/06/2008 | US20080056991 Histamine H3 receptor inhibitors; (4-Azepan-1-ylmethyl-phenyl)-(4-isopropyl-piperazin-1-yl)-methanone dihydrochloride for example; allergies, nasal congestion, eating disorders, sleep disorders, neurodegenerative disorders |
| 03/06/2008 | US20080056987 Inhibitor of Eph receptor kinase; treat angiogenesis, lymphangiogenesis or asculogenesis, disorder of the blood vessels, hyperproliferation of body cells, chronic or acute neurodegenerative disorder; enteral, parenteral and oral administration |
| 03/06/2008 | CA2662197A1 Pharmaceutical compositions of clonazepam and methods of use thereof |
| 03/06/2008 | CA2661870A1 Substituted benzimidazolone derivatives, medicaments comprising them and their use for treating vasopressin-dependent disease |
| 03/06/2008 | CA2661850A1 Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same |
| 03/06/2008 | CA2661800A1 Bifeprunox doses for treating schizophrenia |
| 03/06/2008 | CA2661120A1 Titration schedule for bifeprunox for treating schizophrenia and kits for use therein |
| 03/06/2008 | CA2660431A1 Method of inhibition of respiratory depression using positive allosteric ampa receptor modulators |
| 03/06/2008 | CA2659352A1 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulene derivatives as orexin receptor antagonists |
| 03/06/2008 | CA2655241A1 3-(1h-indol-3-yl)indan-1-ylamine derivatives for the treatment of depression and anxiety |
| 03/05/2008 | EP1895005A1 Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| 03/05/2008 | EP1894930A1 Thiazole derivative |
| 03/05/2008 | EP1894928A1 Heterocyclic fxr binding compounds |
| 03/05/2008 | EP1894572A1 Therapeutic agent and/or prophylactic agent for neurogenic pain |
| 03/05/2008 | EP1893750A1 Amniotic cells and methods for use thereof |
| 03/05/2008 | EP1893617A1 Tricyclic compounds useful as serotonin inhibitors and 5-ht1a agonists and antagonists |
| 03/05/2008 | EP1893613A1 Hexahydro-pyrrolo-isoquinoline compounds for the treatment of cns disorders |
| 03/05/2008 | EP1893610A2 Alpha-(aryl-or heteroaryl-methyl)-beta piperidino propanamide compounds as orl1-receptor antagonists |
| 03/05/2008 | EP1893608A2 Thiazolyl mglur5 antagonists and methods for their use |
| 03/05/2008 | EP1893606A2 Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| 03/05/2008 | EP1893597A2 Ampa receptor potentiators |
| 03/05/2008 | EP1893596A2 Benzoýb¨furane and benzoýb¨thiophene derivatives |
| 03/05/2008 | EP1893593A1 3-phenylazetidine derivatives as dopamine agonists |
| 03/05/2008 | EP1893576A1 Treatment of protein folding disorders |
| 03/05/2008 | EP1893566A1 Cyclohexanesulfonyl derivatives as glyt1 inhibitors to treat schizophrenia |